Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Justin S. Collazo
Observed name:
Justin Collazo
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0009-0002-7252-8974
Observed ORCID:
0009-0002-7252-8974
OpenAlex ID:
A5077288251
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations
2024
·
Asma Dilawari
, James Buturla
, et al.
·
Journal of Clinical Oncology
·
62
PDF
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
2023
·
Deepti Telaraja
, Yvette L. Kasamon
, et al.
·
Clinical Cancer Research
·
48
PDF
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
·
Clinical Cancer Research
·
7
Supplementary Table S6 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Data from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
Supplementary Table S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S5 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S7 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S2 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S2 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Show more works
View as search
Works count:
15
Citation count:
117
H-index:
3
I10-index:
2
Year
Topic
Type